BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31606267)

  • 21. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses.
    Bhuiyan MS; Kalsy A; Arifuzzaman M; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
    Am J Trop Med Hyg; 2020 Sep; 103(3):1032-1038. PubMed ID: 32720632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant protein of Salmonella Typhi induces humoral and cell-mediated immune responses including memory responses.
    Das S; Chowdhury R; Ghosh S; Das S
    Vaccine; 2017 Aug; 35(35 Pt B):4523-4531. PubMed ID: 28739115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
    Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
    Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
    Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
    Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.
    Roggelin L; Vinnemeier CD; Fischer-Herr J; Johnson-Weaver BT; Rolling T; Burchard GD; Staats HF; Cramer JP
    Vaccine; 2015 Aug; 33(33):4141-5. PubMed ID: 26144902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.
    Szu SC; Hunt S; Xie G; Robbins JB; Schneerson R; Gupta RK; Zhao Z; Tan X
    Vaccine; 2013 Apr; 31(15):1970-4. PubMed ID: 23422143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
    Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
    J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.
    Kossaczka Z; Bystricky S; Bryla DA; Shiloach J; Robbins JB; Szu SC
    Infect Immun; 1997 Jun; 65(6):2088-93. PubMed ID: 9169736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
    Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
    Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.
    Acevedo R; Callicó A; Aranguren Y; Zayas C; Valdés Y; Pérez O; García L; Ferro VA; Pérez JL
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S10. PubMed ID: 23458379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
    Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
    J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
    Ali A; An SJ; Cui C; Haque A; Carbis R
    Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.